A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVSV Vaccine in Patients With Ovarian Cancer After Surgery
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a Phase I, single-arm, open-label, prospective, non-randomized, single-center dose-escalation study. The study will evaluate the safety, tolerability, and preliminary activity of the NeoOVSV mRNA-lipid nanoparticle vaccine in patients with stage II/III ovarian cancer after surgery, in combination with standard adjuvant chemotherapy and a PD-1 antibody.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta w wieku 18-75 lat
- •Potwierdzona diagnoza raka jajnika stadium II lub III
- •Przebyta operacja usunięcia guza (całkowicie lub prawie całkowicie)
- •Dostępna próbka tkanki guza do badań (zebrana podczas operacji)
- •Brak widocznych resztek guza w badaniach obrazowych (MRI/CT)
- •Dobry stan ogólny - możliwość chodzenia i wykonywania lekkich zajęć
- •Prawidłowo funkcjonujące narządy wewnętrzne (wątroba, nerki, serce)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 9, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
West China Hospital
Chengdu, China
Trial contact
Nan Lin, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.